Viewing on a PDA? Click here to read this email.
Medical Progress Today
mpt home | sign up

Volume 7, Number 22
June 3, 2010


Second Opinion

FDA's Bad Ad Program

Recently, the FDA announced its new "Bad Ad" program, where physicians could anonymously report ads and sales pitches that potentially violate FDA regulations. For this edition of our Second Opinion forum, we've asked policy experts if they think the FDA's new "Bad Ads" program will increase compliance with FDA marketing regulations and improve patient care, or will it "muddy the water" by allowing anti-pharma groups to deluge the agency with manufactured complaints.
Continue reading . . .


· Medical Device Recalls and the FDA Approval Process, Zuckerman, D. M., Brown, P., Nissen, S. E., Archives of Internal Medicine, 6-14-11
· Patent Reform Gets Key Support in House, Julian Pecquet, The Hill, 6-14-11
· $4.3 Billion Pledged at Vaccine Fund-Raiser, Donald G. McNeil Jr., New York Times, 6-13-2011
· Physicians Leaving Practices for health System Employment, Karen Cheung, FierceHealthcare, 6-13-11

More Headlines >>


· Marco Rubio takes on 'Medi-scare' Marc A. Thiessen, Washington Post, 6-13-11
· 'Vouchercare' Is the Right Name for Medicare Laurence Kotlikoff, Bloomberg, 6-15-11
· Built To Fail: Health Insurance Exchanges Under The Affordable Care Act
· Can Exchanges Help Consumers Get Good Value Insurance? Depends On Where You Live Sabrina Corlette, Kaiser Health News, 6-15-11
· The ObamaCare Bad News Continues Karl Rove, Wall Street Journal, 6-16-11
· ObamaCare's Economic Flaws Doug Holtz-Eakin, Investor's Business Daily, 6-8-11

More Commentary >>


· Why States Are So Miffed about Medicaid — Economics, Politics, and the "Woodwork Effect", Benjamin D. Sommers et al., New England Journal of Medicine, 6-15-11
· Auditing Access to Specialty Care for Children with Public Insurance, Joanna bisgaier et al., New England Journal of Medicine, 6-16-11
· Moving Beyond Fee-For-Service: The Case for Managed Care in Medicaid, Michael Ramlet and Carey Lafferty, American Action Forum, 6-14-11
· The New Gold Rush: Prospectors are Hoping to Mine Opportunities in the Healthcare Industry, Health Research Institute, PricewatershouseCoopers, 6-14-11
· Active Purchasing for Health Insurance Exchanges: An Analysis of Options, Sabrina Corlette and JoAnn Volk, RWJF, 6-14-11

More Research>>

Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research.

For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at, or via telephone at 212.599.7000.

Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at, or via telephone at 212.599.7000.

If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line.

Podcast Series

Dr. Stephen Eck, M.D., Ph.D., is a Hematologist/Oncologist at Eli Lilly & Company with experience in drug development both in academic and commercial settings. Dr. Eck joined Lilly in 2007 as Vice President of Translational Medicine & Pharmacogenomics. In 2009, Dr. Eck assumed leadership of the newly formed Tailored Therapeuttics Hub, a group dedicated exclusively to the development of Lilly’s Personalized Medicine strategy. Dr. Eck reflects on the 10th anniversary of the completion of the Human Genome Project and the future of personalized medicine.

Click here to listen to the podcast.

"We're now seeing many drugs in the mid-to-late stage pipelines of large companies and biotech companies that are the result of the human genome mapping. . . . I think we have to appreciate the fact that from finding the gene to getting the drug is a journey of several years. . . . Equally important, though, is that the genomic revolution has built some tools that will enable personalized medicine."
—Dr. Stephen Eck


Center for Medical Progress 
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000